http://business.highbeam.com/436989/art ... el-chantal
Cioteronel Chantal (USA) discontinued, USA.(Brief Article)
Article from: R & D Focus Drug News | October 7, 2002 | Copyright
Following the closure of its operations in June 1998, Chantal (USA) has terminated development of its nonsteroidal dihydrotestosterone antagonist, cioteronel (CYOCTOL). The agent had been investigated in phase II trials for the treatment of acne and …
************
Prospects looked good in 1989, when Chantal struck a rich deal with E.R. Squibb & Sons, licensing the still-unapproved Cyoctol, which helps fight acne and male pattern baldness. The $22 million deal included a payment of $200,000 a month t keep Chantal afloat. A few months later, however, Squibb was acquired by Bristol-Myers Co., which halted the monthly payments.
In May 1990, Bristol-Myers asked Chantal to accept a less lucrative deal, and Chantal pulled out. Shortly after, Chantal formed a similar, and even more profitable pact with The Upjohn Co., which promised Chantal $23 million and $200,000 a month to license Cyoctol.
The two companies parted ways in February 1993, when Upjohn, claiming it was
unimpressed by Cyoctol's performance in clinical trials, terminated the agreement.
http://www.allbusiness.com/north-americ ... 193-1.html
***************
anti-wrinkle cream. The Securities and Exchange Commission filed a 1996 complaint against Wyatt, a former consultant to Chantal, for selling stock in 1993 based on inside information that Upjohn Co. had terminated a licensing agreement with Chantal following
disappointing clinical test results for an anti-acne drug, cyoctol
http://articles.latimes.com/1997/dec/03 ... s/fi-60013